Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc.（MRSN）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
mrsn · 股价预测 · 19 位分析师（近3月）· FMP · 更新于 2026年3月26日
分析师评级与共识
基于过去 3 个月内 19 位华尔街分析师
Buy
19 位分析师
共识
评级分布
12 个月目标价
High
$17.00
Consensus
$10.00
-65.6% upside
Low
$3.00
Median: $10 · Last Close: $29.08
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$10.00
-65.6% upside
High Target
$17
-41.5%
Low Target
$3
-89.7%
Current Price
$29.08
as of today
Based on analyst price targets, the MRSN stock price prediction for the next 12 months ranges from $3 to $17. The consensus MRSN price forecast of $10.00 implies -65.6% upside from the current price of $29.08.
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $29.15 | ↑ 0.25% |
1-day model range: $29.06–$29.24. Peak: $29.24 (+0.25%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MRSN · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2025-11-13 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2025-11-13 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2025-08-14 | Guggenheim | Maintains | Buy→Buy |
| 2025-08-14 | Truist Securities | Maintains | Buy→Buy |
| 2025-05-16 | Guggenheim | Maintains | Buy→Buy |
| 2025-05-16 | Truist Securities | Maintains | Buy→Buy |
| 2024-08-27 | Citigroup | Maintains | Buy→Buy |
| 2024-08-14 | Baird | Maintains | Neutral→Neutral |
| 2024-03-19 | JP Morgan | Upgrade ↑ | Underweight→Neutral |
Wall Street analysts have recently issued updated ratings on Mersana Therapeutics, Inc. (MRSN) stock. Of the recent 88 rating actions, 9 were upgrades and 12 were downgrades. 19 analysts currently cover MRSN.
分析师推荐趋势
MRSN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$25M
↑ 99.6% YoY
Revenue Next Year
$49M
↑ 93.8% YoY
EPS This Year
$-7.14
EPS Next Year
$-9.59
↑ 34.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast MRSN EPS of $-7.14 for the current fiscal year, based on estimates from 2 analysts. The MRSN revenue forecast is $25M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
MRSN 股价预测由两类独立数据源支撑：来自 19 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。MRSN 的共识目标价为 $10.00（-65.6% 上行空间），分析师共识为 Buy。
MRSN 的短期预测（明日）为 $29.15（+0.25%）。
Mersana Therapeutics, Inc. 在 NASDAQ 上市，代码 MRSN。MRSN 在 2027 年的整体展望偏积极，在覆盖分析师中约 58% 对应 Buy 共识。
常见问题
MRSN 预测 · 8 个问题根据 19 位华尔街分析师，MRSN 的 12 个月平均目标价为 $10.00，最高 $17.00、最低 $3.00。若有图表，中位目标价可在上方查看。相对当前价 $29.08，隐含约 -65.6% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.